A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models

被引：15
|
作者：
Brehmer, Dirk
Wu, Tongfei
Mannens, Geert
Beke, Lijs
Vinken, Petra
Gaffney, Dana
Sun, Weimei
Pande, Vineet
Thuring, Jan-Willem
Millar, Hillary
Poggesi, Italo
Somers, Ivan
Boeckx, An
Parade, Marc
van Heerde, Erika
Nys, Thomas
Yanovich, Carol
Herkert, Barbara
Verhulst, Tinne
Du Jardin, Marc
Meerpoel, Lieven
Moy, Christopher
Diels, Gaston
Viellevoye, Marcel
Schepens, Wim
Poncelet, Alain
Linders, Joannes T.
Lawson, Edward C.
Edwards, James P.
Chetty, Dushen
Laquerre, Sylvie
Lorenzi, Matthew V.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-DDT02-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
DDT02-04
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer
    Charles Brobbey
    Shasha Yin
    Liu Liu
    Lauren E. Ball
    Philip H. Howe
    Joe R. Delaney
    Wenjian Gan
    Scientific Reports, 13
  • [22] Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma
    Allison E. Drew
    Oscar Moradei
    Suzanne L. Jacques
    Nathalie Rioux
    Ann P. Boriack-Sjodin
    Christina Allain
    Margaret Porter Scott
    Lei Jin
    Alejandra Raimondi
    Jessica L. Handler
    Heidi M. Ott
    Ryan G. Kruger
    Michael T. McCabe
    Christopher Sneeringer
    Thomas Riera
    Gideon Shapiro
    Nigel J. Waters
    Lorna H. Mitchell
    Kenneth W. Duncan
    Mikel P. Moyer
    Robert A. Copeland
    Jesse Smith
    Richard Chesworth
    Scott A. Ribich
    Scientific Reports, 7
  • [23] Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma
    Drew, Allison E.
    Moradei, Oscar
    Jacques, Suzanne L.
    Rioux, Nathalie
    Boriack-Sjodin, Ann P.
    Allain, Christina
    Scott, Margaret Porter
    Jin, Lei
    Raimondi, Alejandra
    Handler, Jessica L.
    Ott, Heidi M.
    Kruger, Ryan G.
    McCabe, Michael T.
    Sneeringer, Christopher
    Riera, Thomas
    Shapiro, Gideon
    Waters, Nigel J.
    Mitchell, Lorna H.
    Duncan, Kenneth W.
    Moyer, Mikel P.
    Copeland, Robert A.
    Smith, Jesse
    Chesworth, Richard
    Ribich, Scott A.
    SCIENTIFIC REPORTS, 2017, 7
  • [24] Preclinical characterization of ATG-042-198, a novel MTAP null-selective PRMT5 inhibitor
    Kong, Ya
    Zhang, Ming
    Jiang, Lulu
    Xu, Ruiting
    Jiang, Bin
    Dai, Guoqiang
    He, Yulong
    Liu, Huiling
    Mei, Jay
    Hou, Bing
    Shan, Bo
    CANCER RESEARCH, 2024, 84 (06)
  • [25] PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer
    Huang, Jianhao
    Zheng, Yonghua
    Zheng, Xiao
    Qian, Bao
    Yin, Qi
    Lu, Jingjing
    Lei, Han
    CELL TRANSPLANTATION, 2021, 30
  • [26] The discovery and preclinical characterization of the MTA cooperative PRMT5 inhibitor AM-9747
    Belmontes, Brian
    Policheni, Antonia
    Liu, Siyuan
    Slemmons, Katherine
    Moriguchi, Jodi
    Ma, Hayley
    Aiello, Daniel
    Yang, Yajing
    Vestergaard, Mikkel
    Cowland, Sanne
    Anderson, Jan
    Sarvary, Ian
    Tamayo, Nuria
    Pettus, Liping
    Mukund, Susmith
    Pope, Leszek
    Allen, Jennifer R.
    Glad, Sanne
    Bourbeau, Matthew
    Hughes, Paul E.
    CANCER RESEARCH, 2022, 82 (12)
  • [27] A novel MTA non-competitive PRMT5 inhibitor.
    Malik, Rohit
    Park, Peter K.
    Barbieri, Christopher M.
    Blat, Yuval
    Sheriff, Steven
    Weigelt, Carolyn A.
    Kopcho, Lisa M.
    Celiktas, Muge
    Ruzanov, Max
    Naglich, Joseph G.
    Price, Jennifer L.
    Harner, Mary
    Omalley, Kevin M.
    Deng, Jingjing
    Schmitz, William
    Li, Guo
    Ruan, Zheming
    Qin, Lan-ying
    Duke, Gerald J.
    Rodrigo, Iyoncy
    Witmer, Mark R.
    Harden, David G.
    Demes, Shilpa
    Arey, Brian J.
    Soars, Matt
    Fink, Brian E.
    Gavai, Ashvinikumar V.
    Vite, Gregory D.
    Voliva, Charles F.
    CANCER RESEARCH, 2021, 81 (13)
  • [28] PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy
    Welliver, Meng
    Jin, Feng
    Otterson, Gregory
    Carbone, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S844 - S844
  • [29] Structure-Based Discovery and Biological Assays of a Novel PRMT5 Inhibitor for Non-Small Cell Lung Cancer
    Chen, Yingqing
    Zhang, Mingyu
    Wu, Anxin
    Yao, Xiaojun
    Wang, Qianqian
    MOLECULES, 2022, 27 (21):
  • [30] Targeting PRMT5 enhances the radiosensitivity of tumor cells grown in vitro and in vivo
    Degorre, Charlotte
    Lohard, Steven
    Bobrek, Christina N.
    Rawal, Komal N.
    Kuhn, Skyler
    Tofilon, Philip J.
    SCIENTIFIC REPORTS, 2024, 14 (01):
12345